TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29910024

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 577

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 577
Study: 27131268

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor plus sitagliptin (GS)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 23720411

Group type: EXPERIMENTAL
Intervention: Oral glucose load (75 grams of carbohydrates in 300 mL water)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water (300 mL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral glucose load
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study: 23419911

Group type: EXPERIMENTAL
Intervention: Intervention group performing The11 exercises (2 to 3 sessions per week during one soccer season)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Control group continuing usual warm-up
Number of subjects: 479
Study: 20580111

Group type: EXPERIMENTAL
Intervention: IMRT treatment with dose of the day assessment
Number of subjects: 10
Study: 18713788

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 16621327

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of somatostatin to block GH secretion during the first 3 hours of sleep (mainly SWS)
Number of subjects: 0
Study: 12691793

Group type: EXPERIMENTAL
Intervention: Quetiapine 25‐75 mg/day
Number of subjects: 9
Study: 11205648

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg, 40 mg, and 20 mg in 2-week intervals for 6 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prednisone (during steroid treatment)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (during steroid treatment)
Number of subjects: 39
Study: 9247506

Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.0 to 2.5) plus aspirin (150 mg daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo plus aspirin (150 mg daily)
Number of subjects: 57
Study: 8233735

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of Curosurf (200 mg/kg body weight)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of Curosurf
Number of subjects: 75
Study: 3303425

Group type: EXPERIMENTAL
Intervention: Betamethasone (8 mg) administered intramuscularly for 10 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prednisolone (40 mg) administered orally for 10 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo injections and tablets
Number of subjects: 12
Study: 30768224

Group type: EXPERIMENTAL
Intervention: Abicipar 1 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Abicipar 2 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 50
Study: 28576627

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: BVS
Number of subjects: 240

Group type: COMPARATOR
Intervention: EES and BES
Number of subjects: 240
Study: 26023904

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 23980056

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 50
Study: 22109762

Group type: EXPERIMENTAL
Intervention: Alprazolam orally for 3 months
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Alprazolam plus four intratympanic dexamethasone (ITD) injections
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Alprazolam plus four ITD injections plus four intravenous injections of lipo-prostaglandin E(1)
Number of subjects: 107
Study: 19501780

Group type: EXPERIMENTAL
Intervention: Additional water
Number of subjects: 58
Study: 16415095

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate 100 mg/day
Number of subjects: 287

Group type: COMPARATOR
Intervention: No beta-blocker (control)
Number of subjects: 287
Study: 12576907

Group type: EXPERIMENTAL
Intervention: 4-week multifactorial rehabilitation program
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10-week multifactorial rehabilitation program
Number of subjects: 60
Study: 10856390

Group type: EXPERIMENTAL
Intervention: Medtronic Thera DR pacemaker
Number of subjects: 16
Study: 8799095

Group type: EXPERIMENTAL
Intervention: BOM+
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 1377245

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of gentamicin and metronidazole
Number of subjects: 103

Group type: COMPARATOR
Intervention: Three doses of gentamicin and metronidazole
Number of subjects: 103
Study: 6462404

Group type: EXPERIMENTAL
Intervention: Dexamethasone (steroid) administration during and after lumbar discectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No steroid administration (control group)
Number of subjects: 0
Study: 31477280

Group type: EXPERIMENTAL
Intervention: 22 unique antibodies (survival-associated antibodies, SAAs) used to stratify patients into low-, medium-, or high-risk survival groups.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prognostic proteomic clusters validated from TCGA data.
Number of subjects: 216
Study: 29801482

Group type: EXPERIMENTAL
Intervention: Mwanamphepo (herbal medicine)
Number of subjects: 8219
Study: 25777576

Group type: EXPERIMENTAL
Intervention: Integrative mid-trimester anomaly (IMTA) chart used during examination
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard examination without the IMTA chart
Number of subjects: 25
Study: 24249322

Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 331
Study: 23145756

Group type: COMPARATOR
Intervention: Standard single bundle ACL reconstruction with hamstring tendon autografts
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Augmentation technique with hamstring tendon autograft
Number of subjects: 40
Study: 20708814

Group type: EXPERIMENTAL
Intervention: Sitagliptin administration
Number of subjects: 23
Study: 17701421

Group type: EXPERIMENTAL
Intervention: Muscle Fuel (MF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study: 15812753

Group type: EXPERIMENTAL
Intervention: Left ventricular pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous biventricular pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential biventricular pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CONTAK RENEWAL 2/4/4HE/EASYTRAK 2 system
Number of subjects: 0
Study: 11819020

Group type: EXPERIMENTAL
Intervention: Single-stage closed-wedge tibial osteotomy and anterior cruciate ligament reconstruction
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tibial osteotomy with ligament reconstruction using the Ligament Advanced Reconstruction System
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tibial osteotomy without ligament reconstruction
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tibial osteotomy (overall)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Open-wedge tibial osteotomy
Number of subjects: 14
Study: 9861576

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patients with a history of myocardial infarction and/or hypertension
Number of subjects: 20
Study: 9088584

Group type: EXPERIMENTAL
Intervention: metoprolol CR + fluvastatin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: metoprolol CR + bezafibrate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: atenolol + fluvastatin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: atenolol + bezafibrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 2285326

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (interactive instructional activities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support group intervention (nonstructured discussions)
Number of subjects: 0
Study: 7261411

Group type: EXPERIMENTAL
Intervention: Jejuno-ileal bypass surgery
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lean matched controls
Number of subjects: 19
Study: 31540903

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 31390907

Group type: EXPERIMENTAL
Intervention: Pitavastatin + Ezetimibe
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Pitavastatin Monotherapy
Number of subjects: 1734
Study: 26585728

Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (HFS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-frequency spinal cord stimulation (LFS)
Number of subjects: 12
Study: 24697789

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program in intervention nursing homes
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Comparison nursing homes (no QI program)
Number of subjects: 1497
Study: 21724681

Group type: EXPERIMENTAL
Intervention: 8-week exercise training
Number of subjects: 32
Study: 20605316

Group type: EXPERIMENTAL
Intervention: GreenLight HPS 120-W laser vaporization (PVP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (TURP and PVP)
Number of subjects: 120
Study: 17903266

Group type: EXPERIMENTAL
Intervention: Pharmacist outreach visits on two different topics
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: One-to-one meetings with a pharmacist
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Visit supported by 'traditional' information material
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Visit with 'new' information material
Number of subjects: 2900

Group type: COMPARATOR
Intervention: No visit/material
Number of subjects: 2900
Study: 15616047

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine with 1:400,000 epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study: 12393307

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 11057103

Group type: EXPERIMENTAL
Intervention: RANTES concentrations in BALF from s.A (14.4 pg/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: RANTES concentrations in BALF from s.B (10.9 pg/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: RANTES concentrations in BALF from s.A (from upper lobes)
Number of subjects: 28
Study: 7586312

Group type: COMPARATOR
Intervention: Intravenous bretylium (4.7 g)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (high dose: 1.8 g)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (low dose: 0.2 g)
Number of subjects: 302
Study: 2302368

Group type: EXPERIMENTAL
Intervention: Desflurane (I-653) at 1.8% inspired concentration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Desflurane (I-653) at 5.4% inspired concentration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Desflurane (I-653)
Number of subjects: 10
Study: 86040

Group type: EXPERIMENTAL
Intervention: String capsule for duodenal specimen collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional duodenal tube for duodenal specimen collection
Number of subjects: 0
Study: 30698120

Group type: COMPARATOR
Intervention: Mindfulness Training (MT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Executive Function Training (EFT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No Intervention (NI)
Number of subjects: 96
Study: 28878048

Group type: EXPERIMENTAL
Intervention: Medical management (MM)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Interventional therapy (IT)
Number of subjects: 223
Study: 25855755

Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 23833361

Group type: EXPERIMENTAL
Intervention: Agaricus sylvaticus supplementation (2.1 g/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 21843336

Group type: EXPERIMENTAL
Intervention: Dry cupping treatment (5 sessions over 2 weeks)
Number of subjects: 50
Study: 19853704

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 526

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 526
Study: 17454712

Group type: EXPERIMENTAL
Intervention: Cessation treatment delivered within a randomized clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in smoking levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in nicotine dependence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core symptoms of physiological dependence
Number of subjects: 0
Study: 14756644

Group type: COMPARATOR
Intervention: Single pulse with Candela Vbeam 595-nm pulsed-dye laser
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Multiple stacked pulses (3 or 4) at 1.5-Hz repetition rate
Number of subjects: 25
Study: 11125374

Group type: EXPERIMENTAL
Intervention: 6 core transrectal ultrasound guided prostate biopsy
Number of subjects: 244

Group type: COMPARATOR
Intervention: 12 core transrectal ultrasound guided prostate biopsy
Number of subjects: 244
Study: 9753485

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 9 mg once daily for 8 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Prednisone (PRED) 40 mg once daily for the first 2 weeks tapered to 5 mg/day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Prednisone (PRED)
Number of subjects: 201
Study: 10421972

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (10% solution)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion (5% dextrose)
Number of subjects: 12
Study: 2091171

Group type: EXPERIMENTAL
Intervention: Phosphate ingestion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 402781

Group type: EXPERIMENTAL
Intervention: Intranasal disodium cromoglycate (SCG) 40 mg/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31810731

Group type: EXPERIMENTAL
Intervention: Regular protocolized screening for asymptomatic CAD (annual or second yearly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No further screening for asymptomatic CAD
Number of subjects: 0
Study: 31488762

Group type: EXPERIMENTAL
Intervention: Duloxetine + ASA (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Escitalopram + Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 40
Study: 27912213

Group type: EXPERIMENTAL
Intervention: PLGA/HA grafts
Number of subjects: 8

Group type: COMPARATOR
Intervention: DBB grafts
Number of subjects: 8
Study: 26031187

Group type: EXPERIMENTAL
Intervention: Ondansetron treatment identified by IT method
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Ondansetron treatment identified by VT method
Number of subjects: 251
Study: 23358972

Group type: EXPERIMENTAL
Intervention: Sunitinib plus FOLFIRI (37.5 mg per day, schedule 4/2)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Sunitinib plus FOLFIRI
Number of subjects: 768
Study: 21208106

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg, three times daily for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20074435

Group type: EXPERIMENTAL
Intervention: Ai Chi
Number of subjects: 81

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 81
Study: 16449866

Group type: EXPERIMENTAL
Intervention: Continuous training (n=14, 50% peak work rate)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Interval training (n=10, 100% peak work rate for 30 s, alternating with rest for 30 s)
Number of subjects: 29
Study: 15607042

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 1570
Study: 11327193

Group type: EXPERIMENTAL
Intervention: Timeline Followback (TLFB) method
Number of subjects: 34
Study: 9597554

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.0 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8186343

Group type: EXPERIMENTAL
Intervention: Mesalamine 2 g daily
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Mesalamine 4 g daily
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 2916297

Group type: EXPERIMENTAL
Intervention: New urinary drainage system with PVP‐I release
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard closed drainage system
Number of subjects: 109
Study: 31701562

Group type: EXPERIMENTAL
Intervention: OHS education at school
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Safety training at work
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Quality of OHS education
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Quality of safety training
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Inadequacy in safety training
Number of subjects: 1339
Study: 31599044

Group type: EXPERIMENTAL
Intervention: Aquablation in 30cc to 80cc prostates (WATER trial)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Aquablation in 80cc to 150cc prostates (WATER II trial)
Number of subjects: 217
Study: 28338038

Group type: EXPERIMENTAL
Intervention: School-based dental sealant (light polymerised resin-based sealant with fluoride)
Number of subjects: 276

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 276
Study: 25921849

Group type: EXPERIMENTAL
Intervention: SFA-rich drinks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SFA + LC n-3 PUFA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin infusion with SFA + LC n-3 PUFA
Number of subjects: 30
Study: 23150274

Group type: EXPERIMENTAL
Intervention: Sad-state condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral-state condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disgust condition
Number of subjects: 0
Study: 21224369

Group type: EXPERIMENTAL
Intervention: PK-guided docetaxel dosing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Body surface area-based docetaxel dosing
Number of subjects: 30
Study: 18996055

Group type: EXPERIMENTAL
Intervention: Newly detected AF during the first 3 months of implant (4% incidence, 45 of 1170 patients with no AF)
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: History of AF at the time of ICD implant
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Newly detected AF
Number of subjects: 1530
Study: 16868887

Group type: EXPERIMENTAL
Intervention: Optimized treatment for 16 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (16 healthy age- and BMI-matched subjects)
Number of subjects: 24
Study: 12771395

Group type: EXPERIMENTAL
Intervention: Activating intervention
Number of subjects: 192

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 192
Study: 11273473

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 29

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 29
Study: 9359118

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of both medications
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bipolar II disorder
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: History of rapid cycling
Number of subjects: 51
Study: 1288281

Group type: EXPERIMENTAL
Intervention: Individual packages of support aimed at enhanced social contacts (experimental group, n = 261)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control group (n = 262)
Number of subjects: 523
Study: 3980805

Group type: EXPERIMENTAL
Intervention: Duo formula group treatment (DFGT), facilitated by a fellow sufferer and a physician, in a series of ten 2-hour weekly sessions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duo formula group treatment (DFGT)
Number of subjects: 0
Study: 31370912

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 731
Study: 29231073

Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 26951352

Group type: EXPERIMENTAL
Intervention: C. psittaci real-time polymerase chain reaction (PCR)
Number of subjects: 147
Study: 25376395

Group type: EXPERIMENTAL
Intervention: MVPA > 10 of 200-300 min per week
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: LPA
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: MVPA > 10 and LPA
Number of subjects: 260
Study: 23137503

Group type: EXPERIMENTAL
Intervention: Ticagrelor treatment
Number of subjects: 4295

Group type: COMPARATOR
Intervention: Clopidogrel treatment
Number of subjects: 4295

Group type: EXPERIMENTAL
Intervention: Baseline cystatin C concentration
Number of subjects: 4295

Group type: EXPERIMENTAL
Intervention: Discharge cystatin C concentration
Number of subjects: 4295

Group type: EXPERIMENTAL
Intervention: One month cystatin C concentration
Number of subjects: 4295
Study: 20127870

Group type: EXPERIMENTAL
Intervention: fMRI and ERP measures of face-selectivity
Number of subjects: 0

Group type: COMPARATOR
Intervention: OFA response
Number of subjects: 0
Study: 18603731

Group type: EXPERIMENTAL
Intervention: Cocoa bean husk extract (CBHE) mouth rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 0